425 related articles for article (PubMed ID: 20699418)
21. p27(Kip1) Knockout mice are protected from diabetic nephropathy: evidence for p27(Kip1) haplotype insufficiency.
Wolf G; Schanze A; Stahl RA; Shankland SJ; Amann K
Kidney Int; 2005 Oct; 68(4):1583-9. PubMed ID: 16164635
[TBL] [Abstract][Full Text] [Related]
22. Activation of EphA1-Epha receptor axis attenuates diabetic nephropathy in mice.
Li Y; Yan H; Wang F; Huang S; Zhang Y; Wang Z; Zhong M; Zhang W
Biochem Biophys Res Commun; 2017 May; 486(3):693-699. PubMed ID: 28341121
[TBL] [Abstract][Full Text] [Related]
23. Loss of Farnesoid X receptor (FXR) accelerates dysregulated glucose and renal injury in db/db mice.
Qiu Y; Kang N; Wang X; Yao Y; Cui J; Zhang X; Zheng L
PeerJ; 2023; 11():e16155. PubMed ID: 37790634
[TBL] [Abstract][Full Text] [Related]
24. Antiangiogenic endostatin peptide ameliorates renal alterations in the early stage of a type 1 diabetic nephropathy model.
Ichinose K; Maeshima Y; Yamamoto Y; Kitayama H; Takazawa Y; Hirokoshi K; Sugiyama H; Yamasaki Y; Eguchi K; Makino H
Diabetes; 2005 Oct; 54(10):2891-903. PubMed ID: 16186390
[TBL] [Abstract][Full Text] [Related]
25. Blockade of endothelial-mesenchymal transition by a Smad3 inhibitor delays the early development of streptozotocin-induced diabetic nephropathy.
Li J; Qu X; Yao J; Caruana G; Ricardo SD; Yamamoto Y; Yamamoto H; Bertram JF
Diabetes; 2010 Oct; 59(10):2612-24. PubMed ID: 20682692
[TBL] [Abstract][Full Text] [Related]
26. A dual agonist of farnesoid X receptor (FXR) and the G protein-coupled receptor TGR5, INT-767, reverses age-related kidney disease in mice.
Wang XX; Luo Y; Wang D; Adorini L; Pruzanski M; Dobrinskikh E; Levi M
J Biol Chem; 2017 Jul; 292(29):12018-12024. PubMed ID: 28596381
[TBL] [Abstract][Full Text] [Related]
27. Farnesoid X receptor induces Takeda G-protein receptor 5 cross-talk to regulate bile acid synthesis and hepatic metabolism.
Pathak P; Liu H; Boehme S; Xie C; Krausz KW; Gonzalez F; Chiang JYL
J Biol Chem; 2017 Jun; 292(26):11055-11069. PubMed ID: 28478385
[TBL] [Abstract][Full Text] [Related]
28. N-phenacylthiazolium bromide decreases renal and increases urinary advanced glycation end products excretion without ameliorating diabetic nephropathy in C57BL/6 mice.
Schwedler SB; Verbeke P; Bakala H; Weiss MF; Vilar J; Depreux P; Fourmaintraux E; Striker LJ; Striker GE
Diabetes Obes Metab; 2001 Aug; 3(4):230-9. PubMed ID: 11520302
[TBL] [Abstract][Full Text] [Related]
29. Endogenous fructose production and fructokinase activation mediate renal injury in diabetic nephropathy.
Lanaspa MA; Ishimoto T; Cicerchi C; Tamura Y; Roncal-Jimenez CA; Chen W; Tanabe K; Andres-Hernando A; Orlicky DJ; Finol E; Inaba S; Li N; Rivard CJ; Kosugi T; Sanchez-Lozada LG; Petrash JM; Sautin YY; Ejaz AA; Kitagawa W; Garcia GE; Bonthron DT; Asipu A; Diggle CP; Rodriguez-Iturbe B; Nakagawa T; Johnson RJ
J Am Soc Nephrol; 2014 Nov; 25(11):2526-38. PubMed ID: 24876114
[TBL] [Abstract][Full Text] [Related]
30. Antiatherosclerotic effect of farnesoid X receptor.
Mencarelli A; Renga B; Distrutti E; Fiorucci S
Am J Physiol Heart Circ Physiol; 2009 Feb; 296(2):H272-81. PubMed ID: 19028791
[TBL] [Abstract][Full Text] [Related]
31. Farnesoid X Receptor Agonism Protects against Diabetic Tubulopathy: Potential Add-On Therapy for Diabetic Nephropathy.
Marquardt A; Al-Dabet MM; Ghosh S; Kohli S; Manoharan J; ElWakiel A; Gadi I; Bock F; Nazir S; Wang H; Lindquist JA; Nawroth PP; Madhusudhan T; Mertens PR; Shahzad K; Isermann B
J Am Soc Nephrol; 2017 Nov; 28(11):3182-3189. PubMed ID: 28696246
[TBL] [Abstract][Full Text] [Related]
32. Farnesoid X receptor deficiency induces nonalcoholic steatohepatitis in low-density lipoprotein receptor-knockout mice fed a high-fat diet.
Kong B; Luyendyk JP; Tawfik O; Guo GL
J Pharmacol Exp Ther; 2009 Jan; 328(1):116-22. PubMed ID: 18948497
[TBL] [Abstract][Full Text] [Related]
33. Knockout of farnesoid X receptor gene aggravates cisplatin-induced kidney injury.
Zhang L; Li A; Huang Z; Wang Y; Yi B
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2022 Feb; 47(2):174-182. PubMed ID: 35545407
[TBL] [Abstract][Full Text] [Related]
34. Establishing equivalent diabetes in male and female Nos3-deficient mice results in a comparable onset of diabetic kidney injury.
Tian L; Nikolic-Paterson DJ; Tesch GH
Physiol Rep; 2019 Sep; 7(18):e14197. PubMed ID: 31535473
[TBL] [Abstract][Full Text] [Related]
35. The orphan nuclear receptor small heterodimer partner negatively regulates pancreatic beta cell survival and hyperglycemia in multiple low-dose streptozotocin-induced type 1 diabetic mice.
Noh JR; Hwang JH; Kim YH; Kim KS; Gang GT; Kim SW; Kim DK; Shong M; Lee IK; Choi HS; Lee CH
Int J Biochem Cell Biol; 2013 Aug; 45(8):1538-45. PubMed ID: 23680671
[TBL] [Abstract][Full Text] [Related]
36. Influence of genetic background on albuminuria and kidney injury in Ins2(+/C96Y) (Akita) mice.
Gurley SB; Mach CL; Stegbauer J; Yang J; Snow KP; Hu A; Meyer TW; Coffman TM
Am J Physiol Renal Physiol; 2010 Mar; 298(3):F788-95. PubMed ID: 20042456
[TBL] [Abstract][Full Text] [Related]
37. Farnesoid X receptor activation protects against renal fibrosis via modulation of β-catenin signaling.
Sun DQ; Yuan F; Fu MZ; Zhong MY; Zhang SL; Lu Y; Targher G; Byrne CD; Zheng MH; Yuan WJ
Mol Metab; 2024 Jan; 79():101841. PubMed ID: 38036169
[TBL] [Abstract][Full Text] [Related]
38. Characterization of susceptibility of inbred mouse strains to diabetic nephropathy.
Qi Z; Fujita H; Jin J; Davis LS; Wang Y; Fogo AB; Breyer MD
Diabetes; 2005 Sep; 54(9):2628-37. PubMed ID: 16123351
[TBL] [Abstract][Full Text] [Related]
39. Preventive effects of vasohibin-2-targeting peptide vaccine for diabetic nephropathy.
Nakashima Y; Tanabe K; Mifune T; Nakadoi T; Hayashi H; Nakagami H; Sato Y; Wada J
Am J Physiol Renal Physiol; 2024 Jun; 326(6):F1054-F1065. PubMed ID: 38695075
[TBL] [Abstract][Full Text] [Related]
40. Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor and TGR5 agonist.
Rizzo G; Passeri D; De Franco F; Ciaccioli G; Donadio L; Rizzo G; Orlandi S; Sadeghpour B; Wang XX; Jiang T; Levi M; Pruzanski M; Adorini L
Mol Pharmacol; 2010 Oct; 78(4):617-30. PubMed ID: 20631053
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
